Bora Pharmaceuticals (6472) Stock Overview
Engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
6472 Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Bora Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$408.50 |
| 52 Week High | NT$795.00 |
| 52 Week Low | NT$402.50 |
| Beta | 0.79 |
| 1 Month Change | -15.51% |
| 3 Month Change | -21.74% |
| 1 Year Change | -25.17% |
| 3 Year Change | -12.19% |
| 5 Year Change | 263.85% |
| Change since IPO | 989.82% |
Recent News & Updates
Recent updates
US Facility Modernization Will Secure Future Specialty Success
Strategic shift to high-value CDMO services and facility upgrades has improved margins, driven growth, and positioned the company for market share gains.Cautious Investors Not Rewarding Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Performance Completely
Mar 30
We Think Bora Pharmaceuticals (TWSE:6472) Can Stay On Top Of Its Debt
Jan 20Bora Pharmaceuticals' (TWSE:6472) Earnings Are Weaker Than They Seem
Nov 21Does Bora Pharmaceuticals (TWSE:6472) Deserve A Spot On Your Watchlist?
Oct 04Investors Appear Satisfied With Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Prospects
Jul 18Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?
Jun 13Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Apr 10Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt
Apr 08Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality
Mar 14Shareholder Returns
| 6472 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -3.2% | 1.6% | 4.2% |
| 1Y | -25.2% | 10.9% | 89.1% |
Return vs Industry: 6472 underperformed the TW Pharmaceuticals industry which returned 10.9% over the past year.
Return vs Market: 6472 underperformed the TW Market which returned 89.1% over the past year.
Price Volatility
| 6472 volatility | |
|---|---|
| 6472 Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in TW Market | 11.5% |
| 10% least volatile stocks in TW Market | 2.5% |
Stable Share Price: 6472 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6472's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Bobby Sheng | www.bora-corp.com |
Bora Pharmaceuticals Co., Ltd. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs.
Bora Pharmaceuticals Co., Ltd. Fundamentals Summary
| 6472 fundamental statistics | |
|---|---|
| Market cap | NT$52.83b |
| Earnings (TTM) | NT$4.38b |
| Revenue (TTM) | NT$19.01b |
Is 6472 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6472 income statement (TTM) | |
|---|---|
| Revenue | NT$19.01b |
| Cost of Revenue | NT$11.16b |
| Gross Profit | NT$7.85b |
| Other Expenses | NT$3.47b |
| Earnings | NT$4.38b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 34.52 |
| Gross Margin | 41.30% |
| Net Profit Margin | 23.05% |
| Debt/Equity Ratio | 99.8% |
How did 6472 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/20 14:24 |
| End of Day Share Price | 2026/04/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bora Pharmaceuticals Co., Ltd. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jianzheng Wu | Capital Securities Corporation |
| Chenghsin Lin | J.P. Morgan |
| null null | KGI Securities Co. Ltd. |